Tarsus Pharmaceuticals, Inc. (TARS)

Market Cap	1.98B
Revenue (ttm)	233.67M
Net Income (ttm)	-104.94M
Shares Out	42.01M
EPS (ttm)	-2.72
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	687,745
Open	47.95
Previous Close	47.35
Day's Range	46.44 - 48.00
52-Week Range	20.08 - 57.28
Beta	0.94
Analysts	Strong Buy
Price Target	66.33 (+40.71%)
Earnings Date	May 1, 2025

About TARS

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company’s lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is also developing TP-04 for the treatment of Ocular Rosacea; TP-05 for potential Lyme disease prophylaxis; and community malaria reduction. In addition, the company devel...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 323
• Stock Exchange: NASDAQ
• Ticker Symbol: TARS
• Website: https://www.tarsusrx.com

Financial Performance

In 2024, Tarsus Pharmaceuticals's revenue was $182.95 million, an increase of 948.62% compared to the previous year's $17.45 million. Losses were -$115.55 million, -14.97% less than in 2023.

Analyst Forecast

According to 6 analysts, the average rating for TARS stock is "Strong Buy." The 12-month stock price forecast is $66.33, which is an increase of 40.71% from the latest price.

Price Target

$66.33

(40.71% upside)

Analyst Consensus: Strong Buy